CD4 and neoplasm: At present, in addition to conventional antitumor therapy and recently emerging ICIs, tumor immunotherapy is being developed from different aspects, such as innate immunity (natural killer T (NKT) and natural killer (NK) cell activation) and adaptive immunity (CD4+ and CD8+ T cell activation).